Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation

• Published in: Blood advances Vol. 5; no. 6; pp. 1585 - 1593
• Main Authors: Baumrin, Emily, Izaguirre, Natalie E., Bausk, Bruce, Feeley, Monica M., Bay, Camden P., Yang, Qiheng, Ho, Vincent T., Baden, Lindsey R., Issa, Nicolas C.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 23.03.2021; American Society of Hematology
• Subjects: Clinical Trials and Observations

Allogeneic hematopoietic cell transplantation (HCT) recipients are at increased risk for varicella zoster virus (VZV) reactivation and associated complications. A nonlive adjuvanted recombinant zoster vaccine (RZV) has been developed to prevent herpes zoster (HZ), but there are no recommendations fo...